Published 'success rates' for diabetes stem-cell therapy lack a standard definition and are not comparable across trials. Some report 'improvement' in glucose markers in 40–70% of participants, but assessments are usually unblinded and uncontrolled. Insulin-independence in Type 1 after stem cells is exceptional and unproven in rigorous trials; Type 2 shows variable, modest glucose reduction. Independent reviews highlight methodological weakness.
Two hundred thirty-six registered trials and 26 recruiting studies address stem-cell therapy in diabetes — the largest trial landscape among the conditions here. Small cohorts report modest improvements in insulin secretion and HbA1c, but quality is heterogeneous and controls are often absent. Some report temporary reductions in insulin requirement; durability beyond 12 months is poorly documented. No trial has produced insulin independence in Type 1, and sustained insulin-free control in Type 2 is rare.
Am I a candidate? → · Diabetes (Type 1 & 2): full overview → · Diabetes (Type 1 & 2) cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
רפואה רגנרטיבית מאושרת GMP בלב האיחוד האירופי — החל מ-3,000–8,000 יורו, חלק קטן ממחירי ארהב או גרמניה. פרוטוקולים מותאמים אישית למטופלים מ-50+ מדינות.
בדיקה רפואית חינם